InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
5,841.47
(
-0.02%
)
US TECH 100
19,698.00
(
0.31%
)
Dow Jones
43,239.05
(
0.37%
)
Brent Oil
74.48
(
0.43%
)
Bitcoin
67,997.16
(
0.86%
)
Post# of 253393
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

bladerunner1717

Send PM Follow Ignore
Followers 38
Posts 5652
Boards Moderated 0
Alias Born 11/09/2003

bladerunner1717

Re: DewDiligence post# 132282

Saturday, 12/03/2011 12:00:23 AM

Saturday, December 03, 2011 12:00:23 AM

Post# of 253393
Dew,

I thought it was generally agreed that the "nukes" would be the backbone of an all-oral HCV treatment. So why is BMY spending money testing its NS5A inhibitor with JNJ's TMC435? Could it be possible to have a three-drug combo, each from a different company? (BMY's NS5A inhibitor, JNJ's PI from Medivir and GILD's nuke from VRUS)


Bladerunner
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up